Rockwell Medical, Inc. (RMTI)
USD 1.04
(0.49%)
USD 1.04
(0.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.69 Million USD | 68.79% |
| 2022 | -16.16 Million USD | 39.76% |
| 2021 | -27.79 Million USD | -4.0% |
| 2020 | -26.72 Million USD | 21.67% |
| 2019 | -31.47 Million USD | -9.42% |
| 2018 | -31.47 Million USD | -22.74% |
| 2017 | -25.4 Million USD | -36.35% |
| 2016 | -18.63 Million USD | -30.5% |
| 2015 | -13.59 Million USD | 11.72% |
| 2014 | -16.17 Million USD | 64.8% |
| 2013 | -45.95 Million USD | 13.19% |
| 2012 | -52.93 Million USD | -161.21% |
| 2011 | -20.26 Million USD | -1269.45% |
| 2010 | -1.28 Million USD | 65.16% |
| 2009 | -4.24 Million USD | 40.79% |
| 2008 | -6.95 Million USD | -169.82% |
| 2007 | -2.65 Million USD | 31.5% |
| 2006 | -3.81 Million USD | -641.82% |
| 2005 | 716.27 Thousand USD | -31.05% |
| 2004 | 1.03 Million USD | 61.86% |
| 2003 | 641.83 Thousand USD | 236.46% |
| 2002 | -470.34 Thousand USD | 53.3% |
| 2001 | -1.05 Million USD | -51.32% |
| 2000 | -665.61 Thousand USD | 4.91% |
| 1999 | -700 Thousand USD | 56.25% |
| 1998 | -1.4 Million USD | 0.0% |
| 1997 | -1.6 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.32 Million USD | -617.12% |
| 2024 Q2 | 1.06 Million USD | 248.87% |
| 2023 FY | - USD | 68.79% |
| 2023 Q4 | 3000.00 USD | 100.17% |
| 2023 Q1 | -1.2 Million USD | 37.38% |
| 2023 Q2 | -2.74 Million USD | -127.76% |
| 2023 Q3 | -1.73 Million USD | 36.61% |
| 2022 Q1 | -5.96 Million USD | 22.34% |
| 2022 Q2 | -3.83 Million USD | 35.76% |
| 2022 Q3 | -3.07 Million USD | 19.82% |
| 2022 Q4 | -1.92 Million USD | 37.51% |
| 2022 FY | - USD | 39.76% |
| 2021 Q1 | -6.55 Million USD | 12.43% |
| 2021 Q3 | -6.36 Million USD | 11.42% |
| 2021 Q4 | -7.68 Million USD | -20.7% |
| 2021 Q2 | -7.18 Million USD | -9.62% |
| 2021 FY | - USD | -4.0% |
| 2020 Q2 | -5.81 Million USD | 20.12% |
| 2020 FY | - USD | 21.67% |
| 2020 Q4 | -7.48 Million USD | -21.96% |
| 2020 Q3 | -6.13 Million USD | -5.53% |
| 2020 Q1 | -7.28 Million USD | 1.68% |
| 2019 Q2 | -9.94 Million USD | -21.91% |
| 2019 Q1 | -8.15 Million USD | 13.44% |
| 2019 FY | - USD | -9.42% |
| 2019 Q4 | -7.4 Million USD | -1.59% |
| 2019 Q3 | -7.29 Million USD | 26.67% |
| 2018 Q4 | -9.42 Million USD | -88.55% |
| 2018 Q3 | -4.99 Million USD | 55.03% |
| 2018 FY | - USD | -22.74% |
| 2018 Q1 | -6.56 Million USD | 28.76% |
| 2018 Q2 | -11.11 Million USD | -69.18% |
| 2017 FY | - USD | -36.35% |
| 2017 Q4 | -9.22 Million USD | -88.22% |
| 2017 Q3 | -4.89 Million USD | 25.65% |
| 2017 Q2 | -6.58 Million USD | -36.49% |
| 2017 Q1 | -4.82 Million USD | 4.48% |
| 2016 Q1 | -4.21 Million USD | 30.41% |
| 2016 FY | - USD | -30.5% |
| 2016 Q4 | -5.05 Million USD | -10.73% |
| 2016 Q2 | -5.39 Million USD | -27.79% |
| 2016 Q3 | -4.56 Million USD | 15.35% |
| 2015 Q2 | -2.33 Million USD | 33.08% |
| 2015 Q4 | -6.06 Million USD | -173.77% |
| 2015 FY | - USD | 11.72% |
| 2015 Q1 | -3.49 Million USD | 24.18% |
| 2015 Q3 | -2.21 Million USD | 5.2% |
| 2014 Q2 | -2.31 Million USD | 65.45% |
| 2014 Q4 | -4.6 Million USD | -63.6% |
| 2014 Q3 | -2.81 Million USD | -21.72% |
| 2014 Q1 | -6.69 Million USD | 10.27% |
| 2014 FY | - USD | 64.8% |
| 2013 Q1 | -15.12 Million USD | -12.78% |
| 2013 FY | - USD | 13.19% |
| 2013 Q4 | -7.45 Million USD | 38.35% |
| 2013 Q3 | -12.1 Million USD | -2.8% |
| 2013 Q2 | -11.77 Million USD | 22.2% |
| 2012 Q2 | -11.62 Million USD | -13.0% |
| 2012 Q4 | -13.41 Million USD | 24.96% |
| 2012 FY | - USD | -161.21% |
| 2012 Q1 | -10.28 Million USD | -18.21% |
| 2012 Q3 | -17.87 Million USD | -53.74% |
| 2011 FY | - USD | -1269.45% |
| 2011 Q4 | -8.7 Million USD | -82.8% |
| 2011 Q3 | -4.76 Million USD | -4.93% |
| 2011 Q2 | -4.53 Million USD | -75.77% |
| 2011 Q1 | -2.58 Million USD | -101.26% |
| 2010 Q3 | -419.82 Thousand USD | -192.61% |
| 2010 Q1 | -35.31 Thousand USD | 76.88% |
| 2010 Q2 | 453.32 Thousand USD | 1383.85% |
| 2010 FY | - USD | 65.16% |
| 2010 Q4 | -1.28 Million USD | -205.54% |
| 2009 Q1 | -1.47 Million USD | 47.4% |
| 2009 Q4 | -152.72 Thousand USD | 87.36% |
| 2009 Q2 | -1.4 Million USD | 4.83% |
| 2009 FY | - USD | 40.79% |
| 2009 Q3 | -1.2 Million USD | 14.12% |
| 2008 FY | - USD | -169.82% |
| 2008 Q1 | -1.15 Million USD | -43.44% |
| 2008 Q4 | -2.81 Million USD | -23.8% |
| 2008 Q2 | -935.12 Thousand USD | 19.1% |
| 2008 Q3 | -2.27 Million USD | -142.85% |
| 2007 FY | - USD | 31.5% |
| 2007 Q3 | -172.76 Thousand USD | 29.11% |
| 2007 Q2 | -243.7 Thousand USD | 83.04% |
| 2007 Q1 | -1.43 Million USD | -47.96% |
| 2007 Q4 | -805.84 Thousand USD | -366.45% |
| 2006 FY | - USD | -641.82% |
| 2006 Q3 | -1.44 Million USD | -3.51% |
| 2006 Q1 | -68.77 Thousand USD | -832.66% |
| 2006 Q4 | -971.11 Thousand USD | 32.8% |
| 2006 Q2 | -1.39 Million USD | -1929.9% |
| 2005 Q2 | 290.11 Thousand USD | 463.92% |
| 2005 Q3 | 382.09 Thousand USD | 31.71% |
| 2005 Q4 | -7374.00 USD | -101.93% |
| 2005 FY | - USD | -31.05% |
| 2005 Q1 | 51.44 Thousand USD | -78.42% |
| 2004 Q2 | 251.71 Thousand USD | -6.73% |
| 2004 Q4 | 238.42 Thousand USD | -14.5% |
| 2004 FY | - USD | 61.86% |
| 2004 Q1 | 269.86 Thousand USD | -4.13% |
| 2004 Q3 | 278.87 Thousand USD | 10.79% |
| 2003 Q4 | 281.47 Thousand USD | 21.33% |
| 2003 Q2 | 70.8 Thousand USD | 23.02% |
| 2003 Q1 | 57.56 Thousand USD | 16.76% |
| 2003 FY | - USD | 236.46% |
| 2003 Q3 | 231.98 Thousand USD | 227.62% |
| 2002 Q3 | -37.79 Thousand USD | 85.12% |
| 2002 Q4 | 49.29 Thousand USD | 230.44% |
| 2002 Q1 | -227.94 Thousand USD | 17.52% |
| 2002 FY | - USD | 53.3% |
| 2002 Q2 | -253.9 Thousand USD | -11.4% |
| 2001 Q1 | -104.7 Thousand USD | -176.55% |
| 2001 FY | - USD | -51.32% |
| 2001 Q4 | -276.33 Thousand USD | 17.99% |
| 2001 Q3 | -336.93 Thousand USD | -34.27% |
| 2001 Q2 | -250.93 Thousand USD | -139.66% |
| 2000 Q3 | -209.85 Thousand USD | 20.84% |
| 2000 Q2 | -265.1 Thousand USD | -73.51% |
| 2000 Q1 | -152.78 Thousand USD | -252.79% |
| 2000 Q4 | -37.86 Thousand USD | 81.96% |
| 2000 FY | - USD | 4.91% |
| 1999 Q1 | -215.79 Thousand USD | 0.0% |
| 1999 Q4 | - USD | 150.0% |
| 1999 Q3 | -200 Thousand USD | 33.33% |
| 1999 FY | - USD | 56.25% |
| 1999 Q2 | -300 Thousand USD | -50.0% |
| 1998 Q4 | -200 Thousand USD | 50.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | -400 Thousand USD | -33.33% |
| 1998 Q2 | -300 Thousand USD | 25.0% |
| 1998 Q3 | -400 Thousand USD | -33.33% |
| 1997 Q4 | -300 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 101.522% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -99.659% |
| Embecta Corp. | 245.4 Million USD | 101.913% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 102.882% |
| PainReform Ltd. | -9.56 Million USD | 50.946% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -22.738% |
| SCYNEXIS, Inc. | 73.47 Million USD | 106.388% |
| Journey Medical Corporation | 1.92 Million USD | 344.352% |
| Safety Shot Inc | -12.18 Million USD | 61.478% |
| Alpha Teknova, Inc. | -25.53 Million USD | 81.62% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 104.512% |
| Alvotech | -484.86 Million USD | 99.032% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 104.294% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 497.124% |
| Cosmos Health Inc. | -17.06 Million USD | 72.488% |
| Dynavax Technologies Corporation | 9.66 Million USD | 148.562% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 96.873% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 97.045% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -22.738% |
| Theratechnologies Inc. | -10.31 Million USD | 54.484% |
| Harrow Health, Inc. | 9.72 Million USD | 148.277% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -3.735% |
| Biofrontera Inc. | -18.45 Million USD | 74.562% |
| DURECT Corporation | -24.68 Million USD | 80.984% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 104.777% |
| Cronos Group Inc. | -72.14 Million USD | 93.494% |
| OptiNose, Inc. | -15.55 Million USD | 69.819% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.492% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 86.991% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 117.871% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 113.028% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -19.673% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -560.336% |
| Radius Health, Inc. | 38.31 Million USD | 112.253% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -46.0% |
| ProPhase Labs, Inc. | -14.82 Million USD | 68.342% |
| Phibro Animal Health Corporation | 84.6 Million USD | 105.548% |
| Procaps Group S.A. | 104.02 Million USD | 104.512% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 44.126% |
| Viatris Inc. | 3.51 Billion USD | 100.133% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -363.834% |
| SIGA Technologies, Inc. | 84.15 Million USD | 105.578% |
| Tilray Brands, Inc. | -72.84 Million USD | 93.556% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 678.079% |
| Shineco, Inc. | -26.55 Million USD | 82.323% |
| PetIQ, Inc. | 81.48 Million USD | 105.76% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -29.754% |
| Incannex Healthcare Limited | -18.5 Million USD | 74.633% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 101.128% |
| Alimera Sciences, Inc. | 7.27 Million USD | 164.513% |
| Silver Spike Investment Corp. | 7.34 Million USD | 163.95% |
| Assertio Holdings, Inc. | -222.44 Million USD | 97.89% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -17.625% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -11.447% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 72.066% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 76.566% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 96.852% |
| Hempacco Co., Inc. | -12.77 Million USD | 63.251% |
| Talphera, Inc. | -9.84 Million USD | 52.306% |
| Alvotech | -484.86 Million USD | 99.032% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 106.057% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.956% |
| Currenc Group, Inc. | -1.9 Million USD | -146.978% |
| Kamada Ltd. | 21.53 Million USD | 121.798% |
| Indivior PLC | 66 Million USD | 107.112% |
| Evoke Pharma, Inc. | -7.29 Million USD | 35.631% |
| Flora Growth Corp. | -45.87 Million USD | 89.767% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 76.566% |
| Evolus, Inc. | -41.81 Million USD | 88.773% |
| HUTCHMED (China) Limited | 25.52 Million USD | 118.388% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.944% |
| Akanda Corp. | -27.73 Million USD | 83.076% |